ArticlePloS one2026
Molecular genetic and pregnancy outcomes of fetuses with increased Nuchal Translucency.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIncreased nuchal translucency (NT; ≥ 2.5 mm) is closely associated with various chromosomal abnormalities, structural abnormalities, and genetic diseases. However, research on pathogenic copy number variations (CNVs) affecting pregnancy outcomes in fetuses with increased NT remains limited. This study aimed to summarize the clinical features, chromosomal abnormalities and obstetric outcomes of increased NT to provide a clinical reference for prenatal diagnosis.
methodsA retrospective analysis was conducted on 180 pregnant women with increased NT who underwent invasive prenatal testing via conventional karyotyping and single nucleotide polymorphism (SNP) array analysis between January 2021 and December 2025. These cases were selected from a cohort of 1,678 pregnant women.
resultsChromosomal karyotyping revealed a total of 24 chromosomal abnormalities. Chromosomal polymorphisms were also observed in four cases, including two cases with pericentric inversion of chromosome 9 [inv(9)(p12q13)], one case with 1qh+, and one case with 21pss (double satellites on the short arm of chromosome 21). In addition, SNP-array analysis detected CNVs in 13 fetuses with normal karyotypes. Among the 24 fetuses harboring pathogenic variants, 21 (87.5%) exhibited aneuploidy. These aneuploid cases included 16 fetuses with trisomy 21 syndrome and 5 fetuses with either trisomy 18 syndrome or Klinefelter syndrome, with trisomy 21 accounting for 76.2% (16/21) of the aneuploid cohort. Among the CNVs detected by SNP-array, one was classified as pathogenic, one as likely pathogenic, and the remaining as variants of uncertain significance (VUS). Postnatal follow-up of 10 infants with VUS revealed growth and speech developmental delays in two cases, while no obvious abnormalities were observed in the remaining eight.
conclusionsAneuploidy was found to be the predominant type of abnormality in fetuses with increased NT. This study suggests that high-resolution SNP-array exhibit greater sensitivity in detecting chromosomal microstructural abnormalities and can serve as an effective complement to conventional karyotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.